Main Menu  

Home
About TDI
Isonostic™ Products
Corporate Communications
Careers
Contact Us
Site Map

  Search  


 

  PDF Viewer  

Adobe Reader 6.0 or higher is required to view our PDF documents.





 Commercial Platforms and Products

Complimenting our internal focus on Cancer Isonostics™, TDI also customizes our multiple discovery and clinical platform technologies to other disease areas and to broader challenges in life sciences R&D. Access to TDI technologies is available through collaborative partnerships and services, selected product formats, and negotiated licenses.

Protein Isoform In-Vitro Diagnostics

Isonostics™ - TDI’s unique enabling technology for immuno-affinity capillary electrophoresis bridges the long-standing “missing link” in diagnostic utility: isoform-resolving protein biomarker in-vitro clinical diagnostic assays. TDI’s Isonostics™ technology affinity enriches targeted biomarker families and precisely quantitates the relative abundance of all isoforms of the biomarker, finally allowing the cost-effective clinical utilization of protein isoform information in diagnostics, in toxicology and efficacy studies, and in patient subtyping. TDI will collaborate with partners on the development of customized Application Specific Reagent (ASR) Isonostics™ assay kits for Research Use Only (RUO) clinical diagnostic testing.


Ultra-High Performance Capillary Electrophoresis

EOTrol™ & UltraTrol™ Dynamic Coatings - available through both OEM and direct sales, these products provide selectable electroosmotic force (EOF) control and inhibit protein binding to the walls of the capillary in all modes of capillary electrophoresis. EOTrol™ is designed to be added directly to CE buffers. UltraTrol™ is a precoating that allows CE to be interfaced in hybrid analytical methods (e.g., CE-MS).

Mass Defect Proteomics and Isoformics

IDBEST™ - a highly effective biomarker discovery, target validation and screening platform that leverages stable-isotope paired reagents with mass defect tags to finally allow:
  • affinity enrichment of low abundance target protein families
  • with sub 10% precision in comparative quantitation of isoform-specific varients of targets
  • and good sequence coverage of the target for identity confirmation and isoform detection
all in the same low cost experimental platform. Stable isotopes eliminate sample-to-sample recovery differences in differential display applications or enable absolute quantitation of protein levels through the use of internal standards. The mass defect element eliminates the need for extensive sample clean-up (e.g., multidimensional LC) prior to MS analysis since tagged species are readily discriminated in the mass spectrum with our software. IDBEST™ allows the enrichment of specific low abundance biomarkers by affinity capture or mechanistic baiting of the protein itself, not the tag. IDBEST™ is designed to be both mass spectrometer and operating system agnostic.

  • Toxicology/Efficacy and Target Validation - Cysteine labeling is used for toxicology and efficacy studies and biomarker validation work where simple up and down regulation information is needed. Because only a few peptides are tracked per protein, our cysteine labels allow cost-effective use of multiplexed assays.
  • Biomarker Discovery and Validation - Lysine labeling is used for targeted biomarker discovery and validation because this provides better sequence coverage than cysteine labeling and the ability to identify protein isoforms.

  • IMLS™ - From intact protein to unambiguous N- or C-terminal protein sequence in under 3 minutes using an inexpensive ESI-TOF or tandem MS. Dubbed “sequencing for the masses,” inverted mass ladder sequencing (IMLS™) harnesses the power of mass defect technology for 100-fold more cost-effective protein identifications than tandem MS. Because the protein sequence tag is always produced from a terminus, an IMLS™ protein identification is 90+% unambiguous (compared to 60% by tandem MS).

    Using a tandem MS, IMLS™ provides a means for inexpensive top down protein characterization. Perfect for antigen identification and characterization, the mass of the parent protein is identified and trapped in the first MS stage and its identity determined in the second. Thus, splice variants and post-translational modifications are readily identified without the need for an expensive FTICR analyzer.

  • Identification - IMLS™ provides a cost-effective alternative to identify any purified protein by ESI-TOF. A tandem MS can be used to isolate and identify multiple proteins, if the LC fraction or gel spot contains more than a single protein.

  • Antigen Identification - IMLS™ can be used to identify what protein(s) a therapeutic or diagnostic monoclonal antibody binds to, including what other species or variants may be crossreactive with the antibody. IMLS™ is faster and far more cost-effective than typical bottom up tandem MS methods, where multiple digests are needed to improve sequence coverage so that proteins and their variants can be unambiguously identified.

  • Stable Isotope Metabolomics

    MetaSIRMS™ - Providing a significant cost advantage over traditional radioisotopic methods, Target Discovery has patented the use of stable isotopes for metabolomic studies, including ADME, diagnostics, and biological pathway elucidation. Since stable isotopes can be used in human clinicals, MetaSIRMS™ provides a means to directly validate animal studies in humans.
  • ADME – Stable isotope drug analogs are far cheaper to make and work with than radioisotopes in ADME studies. Using stable isotope ratio mass spectrometric detection methods, recovery differences between experiments are overcome, allowing closure of the material balance comparable to radioisotopic ADME methods. In addition, by using stable isotopes, ADME studies can be directly replicated in humans, providing unequivocal validation of animal models.

  • Metabolic Diagnostics - Stable isotopes provide a convenient method for diagnosing metabolic disorders. Target Discovery is currently using MetaSIRMS™ to investigate the role of diet in autism. If successful, this could become the first chemical diagnostic test for this disorder.

  • Biological Pathway Elucidation - By feeding stable isotope versions of metabolites known to be involved in metabolic pathways of interest, it is possible to quantitatively trace the change in metabolic flux at through the pathway or at branch points in the pathway. This information can be correlated to mRNA or protein expression data to provide a more integrated view of biological pathways and disease.





  •  Copyright © 2017 Target Discovery
     All trademarks and copyrights on this page are owned by their respective owners.

    Web Development by Initsoft